

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	To Be Assigned
		Filing Date	Herewith
		First Named Inventor	Ronald WOOD
		Art Unit	To Be Assigned
		Examiner Name	To Be Assigned
Sheet 1 of 1	Attorney Docket Number	176/61672	

U.S. PATENT DOCUMENTS					
Examiner Initials ¹	Cite No. ²	U.S. Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ³ (if known)			
	1	US 6,376,197 B1	04-23-2002	Keay et al.	
	2	US 6,156,522	12-05-2000	Keay et al.	
	3	US 5,962,645	10-05-1999	Keay et al.	
	4	US 6,232,289 B1	05-15-2001	Keay et al.	
	5	US 5,503,986	04-01-1996	Steers et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials ¹	Cite No. ²	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Y ⁴
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS				
Examiner Initials ¹	Cite No. ²	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ³
	6	Cheong, Y et al., "Investigation for Chronic Pelvic Pain," <i>Reviews in Gynaecological Practice</i> 5:227-236 (2005)		
	7	Westropp et al., "In Vivo Models of Interstitial Cystitis," <i>J Urology</i> 167:694-702 (2002)		
	8	Bouchelouche et al., "Increased Urinary Excretion of Leukotriene E ₄ in Patients with Interstitial Cystitis," <i>Urology</i> 57(Suppl. 6A):128-129 (2001)		
	9	Andersson et al., "Pharmacologic Perspective on the Physiology of the Lower Urinary Tract," <i>Urology</i> 60(Suppl. 5A):13-21 (2002)		
	10	Andersson et al., "Bladder Activation: Afferent Mechanisms," <i>Urology</i> 59(Suppl. 5A):43-50 (2002)		
	11	Juhasz et al., "NO-Induced Migraine Attack: Strong Increase in Plasma Calcitonin Gene-Related Peptide (CGRP) Concentration and Negative Correlation with Platelet Serotonin Release," <i>Pain</i> 106:461-470 (2003)		

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /C.Q./

Examiner Signature	/Celine Qian/	Date Considered	01/29/2010
--------------------	---------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov/ipo/ipo701.pdf. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

⁷ Applicant's unique citation designation number (optional). ⁸ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.